(NASDAQ: TMDX) Transmedics Group's forecast annual revenue growth rate of 25.78% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.23%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.63%.
Transmedics Group's revenue in 2024 is $358,759,000.On average, 6 Wall Street analysts forecast TMDX's revenue for 2024 to be $14,799,547,801, with the lowest TMDX revenue forecast at $14,626,746,301, and the highest TMDX revenue forecast at $15,049,743,024. On average, 6 Wall Street analysts forecast TMDX's revenue for 2025 to be $19,727,926,653, with the lowest TMDX revenue forecast at $18,191,227,597, and the highest TMDX revenue forecast at $21,734,959,369.
In 2026, TMDX is forecast to generate $23,561,484,571 in revenue, with the lowest revenue forecast at $21,608,260,508 and the highest revenue forecast at $28,446,196,017.